Fly Time, page-27

Think of it similar to how ISX was before their technical platform reconfiguration... no material revenue (relative to future potential), but at the beginning of multi pipeline product commercialisation.

Yet to get the tick of approvals from the FDA on multiple products (the COVID19 hype is leveraging the ARDS product which is already in plan), but the approval is as close to certain as you could expect in this space. Other product call outs later this year.

Its a definite quality asymmetric spec investment, but with years of product development and hard nosed management behind it - a few steps elevated above our other friends and has the potential to move very quick. Monthly technicals look like a repeat of the 2010-2011 run.

Check out the following posters as a starter if you're looking to get a handle on whats' what:
- ecoool2
- otherperspective
- wombat777
- vinn

good luck my well travelled ISX friend!